Unknown

Dataset Information

0

Laparoscopic fundoplication versus laparoscopic Roux-en-Y gastric bypass for gastro-oesophageal reflux disease in obese patients: protocol for a randomized clinical trial


ABSTRACT: Abstract

Background

Laparoscopic fundoplication (LF) is the standard surgical procedure for the treatment of gastro-oesophageal reflux disease (GORD). Laparoscopic Roux-en-Y gastric bypass (LRYGB) is commonly performed to achieve weight loss in obese patients, but it also has anti-reflux properties. Hence, in the obese population suffering from GORD, LRYGB could be an alternative to LF. The aim of this trial will be to compare LF and LRYGB in an obese population presenting with GORD and being considered for surgery.

Methods

This will be an investigator-initiated randomized clinical trial. The research population will be obese patients (BMI 30–34.9 with waist circumference more than 88 cm (women) or more than 102 cm (men), or BMI 35–40 with any waist circumference) referred to a public hospital for consideration of anti-reflux surgery. The primary aim of the study will be to determine the efficacy of LF compared with LRYGB on subjective and objective control of GORD. Secondary aims include determining early and late surgical morbidity and the side-effect profile of LF compared with LRYGB and to quantify any non-reflux benefits of LRYGB (including overall quality of life) compared with LF.

Conclusion

This trial will determine whether LRYGB is effective and acceptable as an alternative to LF for the surgical treatment of GORD in obese patients Registration number: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12622000636752p (https://www.anzctr.org.au/). This is an investigator-initiated randomized clinical trial of laparoscopic fundoplication (LF) versus laparoscopic Roux-en-Y gastric bypass (LRYGB) for the treatment of gastro-oesophageal reflux disease (GORD) in obese patients (BMI 30–34.9 with waist circumference more than 88 cm (women) or more than 102 cm (men), or BMI 35–40 with any waist circumference). The primary outcome will be the difference in treatment success (defined as a reduction of 50 per cent of more in the GERD-HRQL score between the preoperative and 1 year values) after LRYGB compared with LF. Secondary outcomes will include identification of any difference in treatment success at 5 years (decrease of 50 per cent of more in the GERD-HRQL score between the preoperative value and the 5-year value), objective measures of GORD at 1 and 5 years (ambulatory pH study and endoscopy), non-GORD gastrointestinal symptom scores at 1 and 5 years, and subjective and objective metrics of overall health at 1 and 5 years.

SUBMITTER:  

PROVIDER: S-EPMC9703586 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9189830 | biostudies-literature
| S-EPMC4648551 | biostudies-literature
| S-EPMC5397550 | biostudies-literature
| S-EPMC6132787 | biostudies-literature
| S-EPMC10017621 | biostudies-literature
| S-EPMC5441098 | biostudies-literature
| S-EPMC1326932 | biostudies-literature
| S-EPMC8041701 | biostudies-literature
| S-EPMC10786997 | biostudies-literature
| S-EPMC10256954 | biostudies-literature